Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

2019255 citationslettergreen Open Access

Authors

Dung T. Le · Sidney Kimmel Comprehensive Cancer Center

Vincent J. Picozzi · Virginia Mason Medical Center

Andrew H. Ko · University of California, San Francisco

Zev A. Wainberg · University of California, Los Angeles

Hedy L. Kindler · University of Chicago Medical Center

Andrea Wang‐Gillam · Washington University in St. Louis

Paul E. Oberstein

Abstract

The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)<i>See related commentary by Salas-Benito et al., p. 5435</i>.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 18, pp. 5493-5502

DOI: 10.1158/1078-0432.ccr-18-2992

Field-Weighted Citation Impact: 13.82